Covaxin interim data shows it is 77.8% effective against symptomatic Covid, gives 65.2% protection from Delta variant: The Lancet
World Health Organization approved Covaxin for use among people aged 18 years and above Bharat Biotech’s Covaxin demonstrates 77.8 per cent efficacy against symptomatic Covid-19, peer-reviewed general medical journal The Lancet confirmed. As per phase-three clinical trials data, Covaxin is also the only Covid-19 vaccine that has demonstrated efficacy data against delta variant at 65.2 … Read more